SearchDictionaryMobileLogin

Peter Andersen Selected Research

Tuberculosis

05/2008Double-blind randomized Phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection.
03/2007Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection.
07/2006Cytokine profiles in tuberculosis patients and healthy subjects in response to complex and single antigens of Mycobacterium tuberculosis.
07/2006Tuberculosis in elephants: antibody responses to defined antigens of Mycobacterium tuberculosis, potential for early diagnosis, and monitoring of treatment.
05/2006The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon.
10/2005Vaccines for tuberculosis: novel concepts and recent progress.
04/2005Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis.
01/2005Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.
10/2004Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model.
07/2004Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts.
04/2003Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak.
02/2002Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis.
02/2002Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients.

Articles by Research Topic

Disease

13Infection
09/2008 - 02/2002
13Tuberculosis
05/2008 - 02/2002
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
05/2006

Drug/Important Bio-Agent (IBA)

8AntigensIBA
07/2006 - 02/2002
3Tuberculin (PPD)IBA
05/2008 - 04/2003
2Liposomes (Liposome)IBA
09/2008 - 03/2007
2Interferon-gamma (Interferon, gamma)IBA
05/2006 - 07/2004
2Interleukin-4 (Interleukin 4)IBA
05/2006 - 06/2004
2VaccinesIBA
10/2005 - 01/2005
1Membrane Proteins (Integral Membrane Proteins)IBA
09/2008
1transforming growth factor-beta type II receptorIBA
05/2006
1PeptidesIBA
03/2006
1T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA
06/2004
1CytokinesIBA
06/2004
1Subunit VaccinesIBA
06/2002
1BCG VaccineIBA
02/2002